VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 14, 2026

Stock Comparison

AbbVie Inc. vs Danaher Corporation

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$389B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

Danaher Corporation

DHR · New York Stock Exchange

Market cap (USD)$170.8B
Gross margin (TTM)61.4%
Operating margin (TTM)22.2%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Danaher Corporation's moat claims, evidence, and risks.

View DHR analysis

Comparison highlights

  • Moat score gap: Danaher Corporation leads (77 / 100 vs 65 / 100 for AbbVie Inc.).
  • Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); Danaher Corporation has 3 segments (41% in Diagnostics).
  • Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; Danaher Corporation has 7 across 3.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

Danaher Corporation

Diagnostics

Market

In vitro diagnostics instruments, consumables, software and services (clinical lab, acute care/POC, pathology, molecular diagnostics)

Geography

Global

Customer

Hospitals, physician offices, reference laboratories, pathology labs, critical care settings

Role

IVD device manufacturer and reagent/test supplier + software/services

Revenue share

41%

Side-by-side metrics

AbbVie Inc.
Danaher Corporation
Ticker / Exchange
ABBV - New York Stock Exchange
DHR - New York Stock Exchange
Market cap (USD)
$389B
$170.8B
Gross margin (TTM)
n/a
61.4%
Operating margin (TTM)
n/a
22.2%
Net margin (TTM)
n/a
14.4%
Sector
Healthcare
Healthcare
Industry
n/a
Medical - Diagnostics & Research
HQ country
US
US
Primary segment
Immunology
Diagnostics
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
77 / 100
Moat domains
Legal, Demand
Demand, Supply, Legal
Last update
2026-01-11
2025-12-22

Moat coverage

Shared moat types

Regulated Standards Pipe

AbbVie Inc. strengths

IP Choke PointBrand Trust

Danaher Corporation strengths

Installed Base ConsumablesDesign In QualificationService Field NetworkOperational ExcellenceLearning Curve YieldSuite Bundling

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

Danaher Corporation segments

Full profile >

Biotechnology

Oligopoly

28.3%

Life Sciences

Oligopoly

30.7%

Diagnostics

Oligopoly

41%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.